AXG vs WRLD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite explosive year-over-year revenue growth of 295.8%, the company is deeply unprofitable with a profit margin of -90.32% and negative ROE and ROA, raising sustainability concerns. Valuation metrics are extreme, with a Price/Sales ratio of 100.76 far exceeding sector averages, while technical indicators show a weakening trend and insider sentiment is tepid at 40/100. The stock’s 1-year surge of +152.2% appears disconnected from fundamentals, increasing vulnerability to correction.
WRLD exhibits significant valuation misalignment, trading at $152.08 despite a Graham Number of $113.74 and an Intrinsic Value of $54.46. The Piotroski F-Score of 4/9 indicates only stable health, while financial performance has deteriorated sharply with a -107.8% YoY EPS growth and four consecutive earnings misses. Bearish insider activity from the CEO and CFO, combined with a technical trend of 0/100, suggests a lack of confidence in current price levels. The company's reliance on subprime installment loans exposes it to high credit risk and regulatory scrutiny.
Compare Another Pair
Related Comparisons
AXG vs WRLD: Head-to-Head Comparison
This page compares Solowin Holdings (AXG) and World Acceptance Corporation (WRLD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.